ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection
ViiV Healthcare today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection. (Source: GSK news)
Source: GSK news - February 15, 2013 Category: Pharmaceuticals Source Type: news
Regulatory update – GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma
GlaxoSmithKline (GSK) plc today announced submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for trametinib (MEK) as monotherapy and in combination with dabrafenib (BRAF) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (Source: GSK news)
Source: GSK news - February 7, 2013 Category: Pharmaceuticals Source Type: news
Results announcement for the fourth quarter 2012
GSK delivers 2012 core EPS of 112.7p and returns £6.3bn to shareholders (Source: GSK news)
Source: GSK news - February 6, 2013 Category: Pharmaceuticals Source Type: news
GSK announces support for AllTrials campaign for clinical data transparency
Campaign calls for full disclosure of clinical trial results and clinical study reports to help drive scientific understanding. (Source: GSK news)
Source: GSK news - February 5, 2013 Category: Pharmaceuticals Source Type: news
GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent
GlaxoSmithKline plc (LSE: GSK) announced today that, pursuant to the voluntary open offer undertaken by its subsidiary, GlaxoSmithKline Pte. Ltd, GSK has successfully increased its stake in GlaxoSmithKline Consumer Healthcare Ltd, its publicly-listed Consumer Healthcare subsidiary in India, from 43.2% to 72.5% (Source: GSK news)
Source: GSK news - February 5, 2013 Category: Pharmaceuticals Source Type: news
GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery
GlaxoSmithKline plc. today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib, its MEK inhibitor as adjuvant therapy for melanoma. (Source: GSK news)
Source: GSK news - February 1, 2013 Category: Pharmaceuticals Source Type: news
GSK response to news article in The Guardian on UK legal proceedings related to Avandia (rosiglitazone)
(Source: GSK news)
Source: GSK news - January 30, 2013 Category: Pharmaceuticals Source Type: news
GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries
GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), a leading Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing countries from polio and other infectious diseases. (Source: GSK news)
Source: GSK news - January 28, 2013 Category: Pharmaceuticals Source Type: news
GSK appoints Hans Wijers to its Board as a Non-Executive Director
GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013. (Source: GSK news)
Source: GSK news - January 24, 2013 Category: Pharmaceuticals Source Type: news
GSK signs up to UK Government’s Public Health Responsibility Deal
Pledge to reduce the sugar and calorie content of Lucozade Energy and Ribena products. (Source: GSK news)
Source: GSK news - January 22, 2013 Category: Pharmaceuticals Source Type: news
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes
(Source: GSK news)
Source: GSK news - January 14, 2013 Category: Pharmaceuticals Source Type: news
GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the European Union for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD). (Source: GSK news)
Source: GSK news - January 9, 2013 Category: Pharmaceuticals Source Type: news
